Vascular-targeted photodynamic of prostate cancer phase with Tookad for recurrent prostate cancer following radiation therapy: initial clinical studies

Robert A. Weersink; Brian C. Wilson; Arjen Bogaards; Mark R. Gertner; Sean R. H. Davidson; Masoom A. Haider; Mostafa Elhilali M.D.; John Trachtenberg M.D.

doi:10.1117/12.704398

23 March 2007 Vascular-targeted photodynamic of prostate cancer phase with Tookad for recurrent prostate cancer following radiation therapy: initial clinical studies

Robert A. Weersink, Brian C. Wilson, Arjen Bogaards, Mark R. Gertner, Sean R. H. Davidson, Masoom A. Haider, Mostafa Elhilali M.D., John Trachtenberg M.D.

Author Affiliations +

Proceedings Volume 6424, Photonic Therapeutics and Diagnostics III; 64241E (2007) https://doi.org/10.1117/12.704398
Event: SPIE BiOS, 2007, San Jose, California, United States

Abstract

We report on the first clinical application of vascular-targeted photodynamic therapy using a bacteriopheophorbide derivative, Tookad, in patients with localized prostate cancer following external beam radiation therapy. Patients received either escalating intravenous drug doses at a fixed light dose or escalated light doses at the highest photosensitizer dose. Two cylindrically diffusing fibers were placed transperineally in the prostate, along with light monitoring fibers in the prostate, urethra and rectum. Treatment response was assessed with 7-day gadolinium-enhanced T1-weighted MRI and 6-month biopsy. Lesion formation was strongly drug and light dose-dependent, with an apparent threshold response. Early biochemical and MRI responses support the clinical potential of TOOKAD-PDT to treat locally-recurrent prostate cancer.

Citation Download Citation

Robert A. Weersink, Brian C. Wilson, Arjen Bogaards, Mark R. Gertner, Sean R. H. Davidson, Masoom A. Haider, Mostafa Elhilali M.D., and John Trachtenberg M.D. "Vascular-targeted photodynamic of prostate cancer phase with Tookad for recurrent prostate cancer following radiation therapy: initial clinical studies", Proc. SPIE 6424, Photonic Therapeutics and Diagnostics III, 64241E (23 March 2007); https://doi.org/10.1117/12.704398

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available